Authors
Latest:
The State of Mining Data Insights in the Life Sciences Industry – 2024 (April 2024)A recent industry-wide survey reveals disconnects and unmet needs pertaining to real-world patient data and analytics that can impact business decision making.
Latest:
Current Status of Biosimilars and Their Impact on PharmacovigilanceAs the market for biosimilars expands, a nuanced approach is needed to balance cost considerations with patient safety and pharmacovigilance efforts.
Latest:
Translating ‘Digital-First’ to Commercial SuccessWhy a fundamental rethinking of how manufacturers engage with healthcare providers, payers, and patients is necessary in today's pharma landscape.
Latest:
Sustaining Pace With Contingent WorkersPandemic workforce trends continue to create challenges for pharma.
Latest:
Word to the Whyse presents: The Science of Engagement*** Time and Date: Tuesday, November 17 I 11:00 am – 2:30 pm EST *** *** On-demand available after final airing until Nov. 17, 2021***
Latest:
Overcoming HCP Engagement Fatigue with Data-Driven InsightsWith a single source of data united under a single privacy policy, pharma marketers are equipped to plan, engage, measure, and optimize a targeted digital marketing model.
Latest:
Why Program Management is the Key to Success for Life Science CompaniesDelivering value with enterprise program management.
Latest:
Trends to Watch in Patient-first Pharma MarketingAs healthcare increasingly shifts to digital, new pharma marketing and patient engagement trends are emerging at the forefront of care. In this podcast, Phreesia Life Sciences and Pharmaceutical Executive discuss how technology is changing healthcare consumers’ expectations and helping to create more personalized experiences focused on connecting the right patients to the right content, care and resources.
Latest:
Industry Game Changer: RWE Impacts on Drug DevelopmentCOVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.
Latest:
Approaching Agentic AI Strategically: Life Sciences Data UtilizationStrategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful progress in how data insights inform commercial decision-making.
Latest:
The Harms of ‘Helicopter Research’ in the Life SciencesHow pharma companies can make justice and integrity a priority.
Latest:
Data Intermediaries/Software Can Speed the Usage of Real-World DataSurvey taken by pharma and CRO executives evaluates how effectively various programs convert RWD into usable data.
Latest:
Open Science and Digital Health: A Brighter Future for Parkinson’s DiseaseCollaborative efforts among researchers, clinicians, and industry are essential to unlock the full potential of digital health in transforming the lives of people with Parkinson's disease.
Latest:
China’s 2022 NRDL ReadoutDespite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.
Latest:
Leverage AI to Lower Cost, Barriers to Cell TherapiesOff-the-shelf cell therapies hold immense promise for revolutionizing precision medicine by offering accessible and affordable treatments. However, overcoming the immune system's rejection and navigating the FDA's approval process are crucial challenges.
Latest:
Harnessing AI for Pharma SalesArtificial intelligence is steadily becoming a game changer for the pharma industry, particularly in commercialization activities, such as sales and marketing—and efforts to help highly sought treatments reach the right patients.
Latest:
How A Self-Service Data Platform for Life Sciences Analytics Can Fast-Track Drug ReadinessOwning a self-service data platform allows emerging pharma and biotech companies to accelerate past data engineering intricacies and focus on ad-hoc analytics to discern how their data can help them meet objectives for clinical operations, medical affairs, and commercial teams.
Latest:
A Crossroads for the Digital Therapeutics Industry. Now is the Time to ActRecent events can provide digital therapeutics companies with clear lessons for the future.
Latest:
Why Machine Learning's Potential in Pharma Relies on Its TransparencyDespite the rapid innovation of machine learning, correct protocols to ensure compliance and trustworthiness must be considered.
Latest:
Overcoming AI Bias Within Life SciencesHow to cultivate trust & connections in life sciences in a time of AI bias.
Latest:
Harnessing the Power of Communities to Combat Healthcare InequitiesBiopharma has a responsibility to meet patients where they are.
Latest:
To Reduce Commercial Risk for Orphan Drugs, Transform ForecastingTo successfully commercialize orphan drugs, companies need to set aside general medicine strategies and adopt a more granular approach to identifying and capitalizing on commercial opportunities.
Latest:
The Leap Forward: Practical Gains for Pharma AI UseExploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.
Latest:
The Emergence of Commercial Health Insurances as an Access Route to the Chinese MarketCommercial Health Insurance may bring more opportunities for market access in China.
